- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05879107
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\xa0Years and Older
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
-
Antwerpen, Belgium, 2000
- GSK Investigational Site
-
Erpent (Namur), Belgium, 5101
- GSK Investigational Site
-
Ghent, Belgium, 9000
- GSK Investigational Site
-
Kluisbergen, Belgium, 9690
- GSK Investigational Site
-
Massemen-Wetteren, Belgium, 9230
- GSK Investigational Site
-
Mechelen, Belgium, 2800
- GSK Investigational Site
-
-
-
-
-
Krakow, Poland, 31-501
- GSK Investigational Site
-
Lodz, Poland, 91-363
- GSK Investigational Site
-
Lublin, Poland, 20-362
- GSK Investigational Site
-
Pulawy, Poland, 24-100
- GSK Investigational Site
-
Staszow, Poland, 28-200
- GSK Investigational Site
-
Warszawa, Poland, 02-793
- GSK Investigational Site
-
Warszawa, Poland, 03-291
- GSK Investigational Site
-
Warszawa, Poland, 00-215
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spain, 08025
- GSK Investigational Site
-
Barcelona, Spain, 08023
- GSK Investigational Site
-
Valencia, Spain, 46015
- GSK Investigational Site
-
-
-
-
Alabama
-
Guntersville, Alabama, United States, 35976
- GSK Investigational Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, United States, 92647
- GSK Investigational Site
-
Modesto, California, United States, 95350
- GSK Investigational Site
-
-
Connecticut
-
Hamden, Connecticut, United States, 06517
- GSK Investigational Site
-
-
Florida
-
Clearwater, Florida, United States, 33756
- GSK Investigational Site
-
DeLand, Florida, United States, 32720
- GSK Investigational Site
-
Jupiter, Florida, United States, 33458
- GSK Investigational Site
-
Largo, Florida, United States, 33777
- GSK Investigational Site
-
Orlando, Florida, United States, 32801
- GSK Investigational Site
-
-
Iowa
-
West Des Moines, Iowa, United States, 50266
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- GSK Investigational Site
-
-
Michigan
-
Troy, Michigan, United States, 48085
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- GSK Investigational Site
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75251
- GSK Investigational Site
-
Frisco, Texas, United States, 75033
- GSK Investigational Site
-
Mesquite, Texas, United States, 75149
- GSK Investigational Site
-
Plano, Texas, United States, 75024
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A male or female ≥60 years of age at the time of the first study intervention administration.
- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Written or witnessed informed consent obtained from the participant prior to any study-specific procedure being performed.
- Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self care and activities of daily living.
- Participants who are medically stable in the opinion of the investigator at the time of first study intervention administration. Participants with chronic stable medical conditions with or without specific treatment, are allowed to participate in this study if considered by the investigator as medically stable.
Exclusion Criteria:
- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
- History of any reaction or hypersensitivity likely to be exacerbated by the study interventions, in particular any history of severe allergic reaction to any vaccine containing diphtheria toxoid, or pneumococcal polysaccharide 23-valent vaccine (PPSV23).
- Participants considered by investigator as suffering from serious or unstable chronic illness.
- Any history of dementia or any medical condition that moderately or severely impairs cognition.
- Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
- Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
- Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
- History of previous vaccination with any licensed or investigational pneumococcal conjugate vaccine, or planned receipt through study participation.
- History of previous vaccination with any licensed or investigational pneumococcal polysaccharide vaccine in the last 5 years from enrollment, or planned receipt through study participation.
- Previous vaccination with any licensed or investigational RSV vaccine
- Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions and ending 30 days after the last study intervention administration, or their planned use during the study period.
Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration. In the case of COVID 19 and inactivated/subunit influenza vaccines, this time window can be decreased to 14 days before and after each study intervention administration. In case of COVID-19 vaccine administration within 14 to 30 days window, the administration of COVID-19 vaccine should be in accordance with local government recommendations.
- Planned or actual administration of adjuvanted quadrivalent influenza vaccine or live influenza vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration.
Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by the public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor or designee is notified accordingly.
- Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
- Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the administration of first dose of study interventions or planned administration during the study period.
- Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first study intervention dose or planned administration during the study period. For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device).
- History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
- Bedridden participants.
- Planned move during the study conduct that prohibits participation until EoS.
- Participation of any study personnel or their immediate dependents, family, or household members.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Co-ad Group
Participants receive both the RSVPreF3 OA investigational vaccine and the PCV20 vaccine on Day 1.
|
One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
Other Names:
One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Other Names:
|
Active Comparator: Control Group
Participants receive the PCV20 vaccine on Day 1 and the RSVPreF3 OA investigational vaccine on Day 31.
|
One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
Other Names:
One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opsonophagocytic (OP) antibody (Ab) titers for each of the pneumococcal vaccine serotype (ST)
Time Frame: 1 month after the PCV20 dose (at Day 31)
|
OP Ab titers are expressed as groups geometric mean titers (GMTs).
|
1 month after the PCV20 dose (at Day 31)
|
RSV-A neutralizing Ab titers
Time Frame: 1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
Ab titers are expressed as GMTs.
|
1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
RSV-B neutralizing Ab titers
Time Frame: 1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
Ab titers are expressed as GMTs.
|
1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RSV-A neutralizing Ab titers expressed as mean geometric increase (MGI) over baseline at 1 month after the RSVPreF3 OA investigational vaccine dose
Time Frame: From Baseline (Day 1) to 1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
From Baseline (Day 1) to 1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
|
RSV-B neutralizing Ab titers expressed as MGI over baseline at 1 month after the RSVPreF3 OA investigational vaccine dose
Time Frame: From Baseline (Day 1) to 1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
From Baseline (Day 1) to 1 month after the RSVPreF3 OA investigational vaccine dose (at Day 31 for the Co-ad group and at Day 61 for the Control group)
|
|
Percentage of participants reporting each solicited administration site adverse event (AE)
Time Frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine (administered on Day 1 and Day 31)
|
The solicited administration site events after vaccination include pain, erythema/redness and swelling.
|
Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine (administered on Day 1 and Day 31)
|
Percentage of participants reporting each solicited systemic AE
Time Frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine (administered on Day 1 and Day 31)
|
The solicited systemic events after vaccination include fever, headache, fatigue, myalgia and arthralgia.
|
Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine (administered on Day 1 and Day 31)
|
Percentage of participants reporting unsolicited AE
Time Frame: Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine (administered on Day 1 and Day 31)
|
An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.
|
Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine (administered on Day 1 and Day 31)
|
Percentage of participants reporting serious adverse events (SAEs) after vaccine administration
Time Frame: From vaccine administration (Day 1) up to end of study (6 months after last vaccination: Month 6 for the Co-ad group and Month 7 for the Control group)
|
From vaccine administration (Day 1) up to end of study (6 months after last vaccination: Month 6 for the Co-ad group and Month 7 for the Control group)
|
|
Percentage of participants reporting potential immune mediated diseased (pIMDs)
Time Frame: From vaccine administration (Day 1) up to end of study (6 months after last vaccination: Month 6 for the Co-ad group and Month 7 for the Control group)
|
Potential immune-mediated disease is a subset of adverse events of special interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
|
From vaccine administration (Day 1) up to end of study (6 months after last vaccination: Month 6 for the Co-ad group and Month 7 for the Control group)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 219276
- 2022-501988-40-00 (Other Identifier: EU CTR number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus Infections
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus ImmunizationPuerto Rico, United States, Australia, Honduras, Mexico
-
EuBiologics Co.,LtdNot yet recruitingRespiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV)
-
Clover Biopharmaceuticals AUS Pty LtdRecruitingRespiratory Syncytial Virus InfectionAustralia
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionChina
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus InfectionUnited States, Puerto Rico
-
PfizerCompletedRespiratory Syncytial Virus InfectionChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedRespiratory Syncytial Virus InfectionHonduras, United States, Chile
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus InfectionJapan
-
Shanghai Ark Biopharmaceutical Co., Ltd.Ark Biosciences Pty Ltd.CompletedRESPIRATORY SYNCYTIAL VIRUS INFECTIONSAustralia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Clinical Trials on RSVPreF3 OA investigational vaccine
-
GlaxoSmithKlineRecruitingRespiratory Syncytial Virus InfectionsUnited States, Australia, Italy, Japan, Spain, Korea, Republic of, Canada, Germany
-
GlaxoSmithKlineActive, not recruitingRespiratory Syncytial Virus InfectionsUnited States, Finland, Germany, Japan, Taiwan
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsUnited States, Canada, Sweden
-
GlaxoSmithKlineActive, not recruitingRespiratory Syncytial Virus InfectionsArgentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsUnited States, Belgium
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsPanama, New Zealand, South Africa
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsUnited States
-
GlaxoSmithKlineNot yet recruitingRespiratory Syncytial Virus InfectionsUnited States, Spain, Belgium, Netherlands
-
GlaxoSmithKlineActive, not recruitingRespiratory Syncytial Virus InfectionsUnited States, Canada, Spain, Finland, Germany, Japan, Estonia, Belgium, South Africa, Korea, Republic of, Italy, Russian Federation, Australia, Mexico, United Kingdom, New Zealand, Poland
-
GlaxoSmithKlineActive, not recruitingRespiratory Syncytial Virus Infections | Respiratory Syncytial VirusesUnited States, Canada